Addex Pharmaceuticals ends migraine prevention study due to live damage.

The problem with drug therapy for migraines and tension-type type headaches is advers drug effects. This current study was discontinued to a higher than expected amount of liver disorders in patients. The company stated "abnormalities of liver function tests that is higher than expected in this population." Previous studies with this drug had not shown this problem.the drug being tested